OR WAIT null SECS
The contract development and manufacturing organization announced the addition of a new building complex that will house its headquarters in Bothell, WA.
On March 29, 2018, AGC Biologics, a contract development and manufacturing organization specializing in the clinical and commercial manufacture of therapeutic proteins, announced plans of a new building complex that will house the company’s headquarters in Bothell, WA.
The new 150,000-square-foot complex is located adjacent to the existing AGC Biologics facility in Bothell. The complex will hold the company’s process development labs and corporate administrative offices and will provide expansion space for additional manufacturing capacity.
According to AGC Biologics, the new facilities allow the company to continue its expansion in the United States and will include a new R&D center dedicated to novel manufacturing technologies for faster development of therapeutic proteins.
“These new state-of-the-art facilities will enable us to meaningfully advance and further integrate the development, manufacturing, and commercial functions within our dynamic global headquarters, as well as provide additional footprint for further manufacturing expansion,” said Gustavo Mahler, president and CEO of AGC Biologics, in a company press release.
In March 2018, the company announcedthe addition of a 2000-L single-use bioreactor to its Berkeley, CA, facility to support its biologics capacity. AGC Biologics is a recent integration of Asahi Glass Company (AGC) Bioscience, a glass and chemical producer under AGC, Biomeva, a contract manufacturing organization, and CMC Biologics, a contract biologics manufacturer, which was announcedin January 2018.
Source: AGC Biologics